clinical trial · NCT06932159
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
Humanis Saglık Anonim Sirketi·phase1·completed·n = 40
Type 2 Diabetes Mellitus (T2DM)Empagliflozin + Linagliptin film-coated tabletsGlyxambi film-coated tablets
brief summary
An open label, balanced, randomized, single dose, two treatment, two sequence, two period, two way crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
started
Dec 23, 2024
primary completion
Mar 7, 2025
completion
Apr 8, 2025
last updated
Apr 17, 2025
official title
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol